Please login to the form below

Not currently logged in
Email:
Password:

Voyager Therapeutics appoints chief financial officer

Jane Pritchett Henderson joins the gene therapy specialist

Voyager Jane HendersonCambridge, Massachusetts-based Voyager Therapeutics has appointed Jane Pritchett Henderson as senior vice president and chief financial officer.

Henderson brings nearly 30 years of life science and finance expertise to the firm, most recently as chief financial and business officer at Kolltan Pharmaceuticals.

Prior to this, she served as vice president of business development at ISTA Pharmaceuticals, chief financial officer and head of business development at Axerion Pharmaceuticals, and chief financial officer and chief business officer at Panacos Pharmaceuticals.

Henderson said: “Voyager has an excellent scientific foundation, world class researchers and clinicians, a stellar leadership team and board.

“This strong foundation combined with the company's recent positive interim phase Ib data from its lead program VY-AADC01 for advanced Parkinson's disease and the opportunity to join a company that has the potential to alter the course of treating devastating CNS diseases is highly attractive.

“I am thrilled to join the Voyager team and meaningfully contribute to the growth of the company by helping to bring the company's deep and rapidly progressing pipeline of innovative gene therapy programs to patients.”

11th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics